{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:58:24Z","timestamp":1789473504598,"version":"build-2803163510"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Asthma is often treated with oral corticosteroids (OCS), despite their association with significant adverse effects. While guidelines recommend minimizing OCS use through alternative therapies and patient-centered approaches, discrepancies between recommendations and real-world practices persist. This study evaluates OCS usage patterns and barriers to adherence to asthma treatment guidelines in Italy, using surveys conducted with healthcare professionals (HCPs) and patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Two cross-sectional surveys were administered between January and March 2024 to HCPs and asthma patients. The surveys assessed OCS prescription practices, treatment adherence, patient involvement, adverse event management, and perceptions of OCS use. Descriptive analysis was performed to identify patterns and highlight gaps in current practices.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The surveys revealed considerable variability in OCS prescribing practices, treatment duration and daily dosages. Over 80% of patients reported using OCS and 18% of HCPs believed that the maximum daily doses of OCS are higher than the guideline-recommended doses. Patients did not feel fully involved in treatment decisions, with over 40% of patients reporting unsatisfactory communication about treatment alternatives or adverse effects. Barriers to optimal care included inadequate access to specialists, inconsistent monitoring protocols, and a lack of multidisciplinary approaches. Both HCPs and patients highlighted the need for clearer definitions of OCS dependency and enhanced tools for tracking treatment adherence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The findings underscore the urgent need for systemic reforms to align clinical practice with guidelines. These include establishing pragmatic definitions for OCS dependency, promoting multidisciplinary care, and leveraging technology for monitoring. Addressing psychosocial factors and empowering patients through education and shared decision-making are also critical.<\/jats:p><\/jats:sec>","DOI":"10.3389\/falgy.2025.1638304","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:27:06Z","timestamp":1760333226000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Use of oral corticosteroids in patients with asthma: how far is clinical practice from the guidelines? Results from surveys of patients and doctors"],"prefix":"10.3389","volume":"6","author":[{"given":"Luisa","family":"Brussino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianna","family":"Camiciottoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Stassaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Bagnasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Barbaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Beatrice","family":"Bil\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Cutrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Nicolosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Nour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Scioscia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Walter","family":"Canonica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"101936","DOI":"10.1016\/j.eclinm.2023.101936","article-title":"Global burden of chronic respiratory diseases and risk factors, 1990\u20132019: an update from the global burden of disease study 2019","volume":"59","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.4168\/aair.2023.15.4.473","article-title":"Global disease burden and attributable risk factor analysis of asthma in 204 countries and territories from 1990 to 2019","volume":"15","author":"Liu","year":"2023","journal-title":"Allergy Asthma Immunol Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5588\/ijtld.22.1010","article-title":"The global asthma report 2022","volume":"26","year":"2022","journal-title":"Int J Tuberc Lung Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"PA2074","DOI":"10.1183\/13993003.congress-2023.pa2074","article-title":"Global, regional, and national trends in incidence of asthma: findings from the global burden of disease study 2019","volume":"62","author":"Xing","year":"2023","journal-title":"Eur Respir J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s10198-024-01736-5","article-title":"The economic burden of asthma in Italy: evaluating the potential impact of different treatments in adult patients with severe eosinophilic asthma","volume":"26","author":"Scortichini","year":"2024","journal-title":"Eur J Health Econ"},{"key":"B6","doi-asserted-by":"publisher","first-page":"100007","DOI":"10.1016\/j.waojou.2018.12.001","article-title":"Shadow cost of oral corticosteroids-related adverse events: a pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry","volume":"12","author":"Canonica","year":"2019","journal-title":"World Allergy Organ J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s12325-022-02098-1","article-title":"Clinical remission in severe asthma: a pooled post hoc analysis of the patient journey with benralizumab","volume":"39","author":"Menzies-Gow","year":"2022","journal-title":"Adv Ther"},{"key":"B8","article-title":"Global Strategy for Asthma Management and Prevention, 2024","year":""},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MOO.0000000000000421","article-title":"Risks and management of long-term corticosteroid use in chronic rhinosinusitis","volume":"26","author":"Campbell","year":"2018","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1016\/j.jaip.2022.05.031","article-title":"The contribution of oral and inhaled glucocorticoids to adrenal insufficiency in asthma","volume":"10","author":"Brennan","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13052-017-0348-x","article-title":"Management of acute respiratory diseases in the pediatric population: the role of oral corticosteroids","volume":"43","author":"Cutrera","year":"2017","journal-title":"Ital J Pediatr"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1111\/all.13874","article-title":"Oral corticosteroid use, morbidity and mortality in asthma: a nationwide prospective cohort study in Sweden","volume":"74","author":"Ekstrom","year":"2019","journal-title":"Allergy"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1900804","DOI":"10.1183\/13993003.00804-2019","article-title":"Increased mortality in patients with corticosteroid-dependent asthma: a nationwide population-based study","volume":"54","author":"Lee","year":"2019","journal-title":"Eur Respir J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","article-title":"Systematic literature review of systemic corticosteroid use for asthma management","volume":"201","author":"Bleecker","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"316","DOI":"10.5694\/mja2.50758","article-title":"Cumulative dispensing of high oral corticosteroid doses for treating asthma in Australia","volume":"213","author":"Hew","year":"2020","journal-title":"Med J Aust"},{"key":"B16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1159\/000518514","article-title":"Overuse of oral corticosteroids, underuse of inhaled corticosteroids, and implications for biologic therapy in asthma","volume":"101","author":"Eger","year":"2022","journal-title":"Respiration"},{"key":"B17","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1080\/02770903.2020.1748048","article-title":"Perception of oral corticosteroids in adult patients with asthma in France","volume":"58","author":"Jaffuel","year":"2021","journal-title":"J Asthma"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.jaip.2018.10.016","article-title":"The severe asthma network in Italy: findings and perspectives","volume":"7","author":"Heffler","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1080\/02770903.2024.2338863","article-title":"Asthma management, focused on the use of oral corticosteroids: the opinions of Italian asthmatic patients","volume":"61","author":"Latorre","year":"2024","journal-title":"J Asthma"},{"key":"B20","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1164\/rccm.202007-2721OC","article-title":"Expert consensus on the tapering of oral corticosteroids for the treatment of asthma. A delphi study","volume":"203","author":"Suehs","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2500\/aap.2012.33.3499","article-title":"Practice patterns for oral corticosteroid burst therapy in the outpatient management of acute asthma exacerbations","volume":"33","author":"Fuhlbrigge","year":"2012","journal-title":"Allergy Asthma Proc"},{"key":"B22","doi-asserted-by":"publisher","first-page":"106156","DOI":"10.1016\/j.rmed.2020.106156","article-title":"The effects of oral corticosteroids on lung function, type-2 biomarkers and patient-reported outcomes in stable asthma: a systematic review and meta-analysis","volume":"173","author":"Busby","year":"2020","journal-title":"Respir Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/archdischild-2015-309522","article-title":"Systematic review of the toxicity of short-course oral corticosteroids in children","volume":"101","author":"Aljebab","year":"2016","journal-title":"Arch Dis Child"},{"key":"B24","doi-asserted-by":"publisher","first-page":"190151","DOI":"10.1183\/16000617.0151-2019","article-title":"Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety","volume":"29","author":"Price","year":"2020","journal-title":"Eur Respir Rev"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12931-020-01503-z","article-title":"SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma","volume":"21","author":"Wechsler","year":"2020","journal-title":"Respir Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1007\/s12325-023-02479-0","article-title":"A charter to fundamentally change the role of oral corticosteroids in the management of asthma","volume":"40","author":"Haughney","year":"2023","journal-title":"Adv Ther"},{"key":"B30","doi-asserted-by":"publisher","first-page":"105189","DOI":"10.1016\/j.phrs.2020.105189","article-title":"Why do some asthma patients respond poorly to glucocorticoid therapy?","volume":"160","author":"Henderson","year":"2020","journal-title":"Pharmacol Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/thoraxjnl-2015-207630","article-title":"Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the optimum patient care research database and the British thoracic difficult asthma registry","volume":"71","author":"Sweeney","year":"2016","journal-title":"Thorax"},{"key":"B32","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaci.2017.04.009","article-title":"Oral corticosteroid exposure and adverse effects in asthmatic patients","volume":"141","author":"Sullivan","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s11136-014-0801-x","article-title":"A qualitative study of the impact of severe asthma and its treatment showing that treatment burden is neglected in existing asthma assessment scales","volume":"24","author":"Hyland","year":"2015","journal-title":"Qual Life Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"j1415","DOI":"10.1136\/bmj.j1415","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"Br Med J"},{"key":"B35","doi-asserted-by":"publisher","first-page":"100726","DOI":"10.1016\/j.waojou.2022.100726","article-title":"Systemic corticosteroids in asthma: a call to action from world allergy organization and respiratory effectiveness group","volume":"15","author":"Bleecker","year":"2022","journal-title":"World Allergy Organ J"},{"key":"B36","article-title":"What is severe asthma?, (2025)","year":""},{"key":"B37","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"B38","article-title":"Oral Corticosteroid Stewardship Statement, (2018)","year":""},{"key":"B39","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2147\/JAA.S176026","article-title":"Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study","volume":"11","author":"Price","year":"2018","journal-title":"J Asthma Allergy"},{"key":"B40","doi-asserted-by":"publisher","first-page":"100464","DOI":"10.1016\/j.waojou.2020.100464","article-title":"Oral corticosteroid sparing with biologics in severe asthma: a remark of the Severe Asthma Network in Italy (SANI)","volume":"13","author":"Canonica","year":"2020","journal-title":"World Allergy Organ J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1210\/clinem\/dgae250","article-title":"European society of endocrinology and endocrine society joint clinical guideline: diagnosis and therapy of glucocorticoid-induced adrenal insufficiency","volume":"109","author":"Beuschlein","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B42","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1089\/jop.2019.0058","article-title":"When to consider bisphosphonates in patients on steroids for chronic ocular inflammatory conditions","volume":"35","author":"Takhar","year":"2019","journal-title":"J Ocul Pharmacol Ther"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1902363","DOI":"10.1183\/13993003.02363-2019","article-title":"Oral corticosteroid prescription patterns for asthma in France, Germany, Italy and the UK","volume":"55","author":"Tran","year":"2020","journal-title":"Eur Respir J"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1800703","DOI":"10.1183\/13993003.00703-2018","article-title":"Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature","volume":"52","author":"Volmer","year":"2018","journal-title":"Eur Respir J"},{"key":"B45","doi-asserted-by":"publisher","first-page":"105946","DOI":"10.1016\/j.rmed.2020.105946","article-title":"Patterns of oral corticosteroids use in primary care patients with severe asthma","volume":"166","author":"Vetrano","year":"2020","journal-title":"Respir Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.2147\/JAA.S480380","article-title":"Maintenance OCS were used more frequently than biologics in patients with uncontrolled GINA 4\/5 asthma in Germany in 2019","volume":"17","author":"Milger","year":"2024","journal-title":"J Asthma Allergy"},{"key":"B47","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/ACI.0b013e32832b4651","article-title":"Why do doctors and patients not follow guidelines?","volume":"9","author":"Baiardini","year":"2009","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"15026","DOI":"10.1038\/npjpcrm.2015.26","article-title":"Patient-reported side effects, concerns and adherence to corticosteroid treatment for asthma, and comparison with physician estimates of side-effect prevalence: a UK-wide, cross-sectional study","volume":"25","author":"Cooper","year":"2015","journal-title":"NPJ Prim Care Respir Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s12931-022-02266-5","article-title":"Associations of symptoms of anxiety and depression with health-status, asthma control, dyspnoea, dysfunction breathing and obesity in people with severe asthma","volume":"23","author":"Stubbs","year":"2022","journal-title":"Respir Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1221648","DOI":"10.3389\/fpsyg.2023.1221648","article-title":"Alexithymia and asthma: a systematic review","volume":"14","author":"Silvestro","year":"2023","journal-title":"Front Psychol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3390\/jpm13050833","article-title":"Oral corticosteroid abuse and self-prescription in Italy: a perspective from community pharmacists and sales reports before and during the COVID-19 era","volume":"13","author":"Nappi","year":"2023","journal-title":"J Pers Med"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1638304\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:27:07Z","timestamp":1760333227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1638304\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":51,"alternative-id":["10.3389\/falgy.2025.1638304"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2025.1638304","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"article-number":"1638304"}}